Immunosuppression withdrawal

DRUG8 trials

Conditions

Autoimmune HepatitisHepatitis CHepatitis C, ChronicImmunosuppressionLiver DiseaseLiver TransplantLiver Transplant RecipientsLiver Transplantation

Phase 1

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

CompletedNCT00320606

National Institute of Allergy and Infectious Diseases (NIAID)Liver Transplant, Liver Transplantation

Start: 2006-06-05End: 2017-03-13Updated: 2018-09-20

Phase 2

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

CompletedNCT00105235

National Institute of Allergy and Infectious Diseases (NIAID)Liver Disease, Liver Transplantation

Start: 2005-06-30End: 2011-03-31Updated: 2012-12-27

Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant

CompletedNCT00135694

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure

Start: 2005-10-31End: 2015-09-30Updated: 2019-02-04

Withdrawal of Immunosuppression in Long Term Stable Liver Transplant Recipients

NCT01198314

The Catholic University of KoreaLiver Transplantation

Start: 2010-07-31End: 2013-03-31Target: 20Updated: 2010-09-10

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

CompletedNCT01638559

National Institute of Allergy and Infectious Diseases (NIAID)Immunosuppression, Liver Transplantation, Liver Transplant Recipients

Start: 2012-08-14End: 2018-06-11Updated: 2019-10-07

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

CompletedNCT02533180

National Institute of Allergy and Infectious Diseases (NIAID)Liver Transplant, Liver Transplantation

Start: 2015-12-15End: 2022-07-08Updated: 2023-09-14

Unknown Phase

Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis

NCT03711669

Hospital Clinic of BarcelonaAutoimmune Hepatitis

Start: 2018-01-10End: 2021-04-30Target: 96Updated: 2020-02-12

Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver Transplantation

Enrolling by invitationNCT07735650

Chang Gung Memorial HospitalLiver Transplantation, Liver Transplantation in Long-term

Start: 2025-08-01End: 2027-07-31Target: 60Updated: 2026-07-30

Related Papers

Donor-specific immune senescence as a candidate biomarker of operational tolerance following liver transplantation in adults: Results of a prospective, multicenter cohort study.

2024-11-043 citations

Next‐generation pathology detection of T cell–antigen‐presenting cell immune synapses in human liver allografts

Hepatology2022-07-1229 citations

Impact of Donor and Recipient Clinical Characteristics and Hepatic Histology on Steatosis/Fibrosis Following Liver Transplantation

Transplantation2021-02-2510 citations

Five‐year histological and serological follow‐up of operationally tolerant pediatric liver transplant recipients enrolled in WISP‐R

Hepatology2016-06-1594 citations